NKTR
Nektar Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.95 / 10
Netural
Analyst coverage leans strong‑buy (66.7%) but past performance is poor, with zero win‑rate. Fund‑flow score is 7.9/10, showing strong inflows from large investors and positive overall trend, offset by weak small‑investor outflows.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
67%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-17
InstitutionTD Cowen
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for NKTR?
- NKTR holds a Bearish analyst rating, with 67% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.95/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
